On May 18, 2026, Insulet Corp (PODD) shares rose 3.5% to a current price of $152.49. Over the past 52 weeks, the stock has fluctuated between a high of $354.88

Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Insulet delivered robust Q1 2026 results, with revenue up 34% to $762M and operating margins expanding to 17.5%. Insulet raised full-year guidance to 21-23% sales growth and expects adjusted earnings to exceed $6.25 per share, reflecting strong Omnipod 5 adoption. Valuation has rebounded, with shares trading at 70x forward earnings and 10x sales, leaving little room for error amid decelerating growth.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran's peace counteroffer dismissal on Monday. The stock market opened lower on the rejection of President Trump's peace offering, but buyers once again circled the... Here Are Tuesday's Top Wall Street Analyst Research Calls: Autodesk, Celanese, DexCom, FormFactor, GitLab, Lowe's, Matador Resources, Toast and More

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Insulet Corporation (PODD) Q1 2026 Earnings Call Transcript

Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Insulet (PODD) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $1.02 per share a year ago.

Insulet raised its annual revenue growth forecast on Wednesday after reporting better-than-expected quarterly results, ​driven by strong demand for its tubeless ‌insulin pumps that eliminate the need for daily injections.